Atom Investors LP Makes New Investment in DaVita Inc. (NYSE:DVA)

Atom Investors LP purchased a new stake in DaVita Inc. (NYSE:DVA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 24,977 shares of the company’s stock, valued at approximately $4,094,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in DaVita by 1.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company’s stock worth $776,000 after acquiring an additional 70 shares during the last quarter. Wedmont Private Capital boosted its stake in shares of DaVita by 4.4% in the 3rd quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock valued at $280,000 after purchasing an additional 75 shares during the last quarter. Blue Trust Inc. increased its position in shares of DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after buying an additional 78 shares during the period. First Trust Direct Indexing L.P. lifted its holdings in DaVita by 2.9% in the third quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company’s stock valued at $500,000 after buying an additional 86 shares during the period. Finally, Nisa Investment Advisors LLC grew its holdings in DaVita by 0.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 36,820 shares of the company’s stock worth $6,036,000 after acquiring an additional 126 shares during the period. 90.12% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This trade represents a 5.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.00% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on DVA shares. UBS Group raised their target price on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. Truist Financial raised their price objective on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Finally, Barclays upped their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $161.80.

DaVita Stock Performance

Shares of DaVita stock opened at $166.17 on Monday. The business’s fifty day simple moving average is $158.57 and its 200 day simple moving average is $149.39. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. DaVita Inc. has a 12 month low of $99.18 and a 12 month high of $169.51. The firm has a market capitalization of $13.63 billion, a P/E ratio of 17.93, a price-to-earnings-growth ratio of 0.94 and a beta of 0.89.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same period last year, the firm posted $2.85 earnings per share. DaVita’s quarterly revenue was up 4.6% compared to the same quarter last year. As a group, analysts anticipate that DaVita Inc. will post 9.71 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.